Biosimilar Antibodies

The Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets Melanotransferrin, also known as CD228. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145.16 kDa. For isotype control experiments, the Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the biological functions and pathological roles of Melanotransferrin/CD228.

MEDI-3617 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Angiopoietin-2 (Ang2/ANGPT2). This antibody is comprised of a human IgG2 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For isotype control, it is recommended to use Human IgG2 kappa, Isotype Control. MEDI-3617 is designed for precise binding and neutralization of Ang2, making it highly relevant for research into vascular development and angiogenic processes.

Ansuvimab-zyk is a recombinant human monoclonal IgG1 antibody designed to target and neutralize Zaire ebolavirus. It functions by specifically binding to the viral glycoprotein, thereby inhibiting the virus's ability to enter and infect host cells. This interaction is crucial for preventing the spread of infection and is a key mechanism in its antiviral efficacy against Zaire ebolavirus.

Pritumumab is a naturally derived human monoclonal antibody of the IgG1 kappa subclass, initially isolated from a regional draining lymph node in a patient diagnosed with cervical carcinoma. This antibody specifically targets vimentin displayed on the surface of malignant tumor cells. It is particularly useful in the study of glioblastoma, offering potential insights into the pathology and therapeutic targeting of this aggressive cancer type.

Demcizumab (OMP 21M18) is a monoclonal antibody targeting DLL4, a critical regulator in the Notch signaling pathway. This antibody acts as a potent inhibitor of the Notch pathway, which plays a significant role in cell differentiation, proliferation, and apoptosis. The inhibition of this pathway by Demcizumab has demonstrated efficacy in various cancer models, both as a standalone treatment and in combination with chemotherapy. This makes it a valuable tool for research in cancer biology, particularly in studies exploring the role of Notch signaling in tumorigenesis and therapeutic resistance.

The Anti-NKG2D/CD314 Antibody (1D11) is a chimeric mouse monoclonal antibody of the IgG1, κ subclass, specifically designed to target human NKG2D/CD314. This antibody selectively binds to the NKG2D receptor, a key player in immune cell activation. For accurate isotype control in experimental assays, it is recommended to use Mouse IgG1 kappa, Isotype Control. This antibody is ideal for use in research focused on immune response modulation and the study of diseases where NKG2D signaling is implicated.

Satumomab is a monoclonal antibody of the IgG4-G2a κ isotype, specifically targeting the tumor-associated glycoprotein 72 (TAG-72). This antibody is designed for the precise detection and study of TAG-72 expression in various cancer types, facilitating research into tumor biology and potential therapeutic targets.

Matuzumab (EMD 72000) is a humanized monoclonal antibody designed to target and inhibit the epidermal growth factor receptor (EGFR). By binding to EGFR, Matuzumab prevents its activation and the subsequent downstream signaling pathways, effectively inhibiting tumor growth. This antibody is utilized primarily in research focused on cancer biology, particularly in studies investigating the mechanisms of tumor progression and therapeutic intervention.

Alacizumab is a humanized monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target VEGFR2/KDR/CD309. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, resulting in a predicted molecular weight of 144.08 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. Alacizumab is applicable in research focused on angiogenesis and vascular biology due to its specificity in binding to VEGFR2/KDR/CD309, a critical receptor in vascular endothelial growth factor (VEGF) signaling pathways.

Cifurtilimab (SEA-CD40) is an agonistic, non-fucosylated human IgG1 monoclonal antibody that targets CD40, a co-stimulatory protein found on antigen-presenting cells. This antibody has been engineered to enhance immune activation and exhibits significant antitumor activities, making it a valuable tool for research in cancer immunotherapy.

Ripertamab (SCT400) is a recombinant, chimeric monoclonal antibody (mAb) composed of human and mouse sequences. This antibody is of the IgG1κ isotype and targets the CD20 antigen, a cell surface protein primarily expressed on B cells. Ripertamab is specifically designed for use in research focused on hematological malignancies, such as non-Hodgkin’s lymphoma (NHL), providing a valuable tool for studies aimed at understanding and potentially treating these diseases.

Lumiliximab, a recombinant anti-CD23 monoclonal antibody, effectively inhibits allergen-induced responses by targeting the CD23 receptor. This antibody serves as a crucial tool in immunological research, particularly in studies related to allergic reactions and immune regulation. Lumiliximab's specificity for CD23 makes it ideal for investigating the role of this receptor in various immunological processes and potential therapeutic applications.

Istiratumab (M-6495) is a bispecific monoclonal antibody designed to target both the Insulin-like Growth Factor 1 Receptor (IGF-1R) and the ErbB3 receptor. This antibody facilitates the degradation of these receptors via the proteasome pathway, a mechanism that may be critical in modulating cellular growth and survival pathways. Istiratumab is primarily used in cancer research, where it serves as a tool to investigate the role of IGF-1R and ErbB3 in tumor biology and therapeutic response.

Anvatabart is a human IgG1 κ monoclonal antibody targeting ERBB2. For accurate control experiments, it is recommended to use Human IgG1 kappa as an isotype control.

Atrosimab (ATM-001) is an engineered Fv-Fc1κ fusion protein that exhibits high-affinity binding to human TNF receptor 1 (TNFR1), demonstrated by an EC50 of 0.37 nM. This biologic effectively inhibits TNF-induced activation of TNFR1, highlighting its utility in the investigation of chronic inflammatory diseases. Atrosimab represents a valuable tool for researchers studying the molecular pathways involved in inflammation and immune response.

Brivestobart is a human monoclonal antibody of the IgG4κ subtype designed to target LAG3. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity makes Brivestobart suitable for research focused on the modulation of immune checkpoint pathways, particularly in the context of immunotherapy and cancer research.

Rulonilimab, a human IgG1 monoclonal antibody, selectively targets and binds to the programmed death-1 (PD-1) receptor, effectively inhibiting its interaction with PD-L1 and PD-L2. This inhibition disrupts downstream signaling pathways, thereby enhancing T-cell function and potentially exerting robust anti-tumor activity through immune checkpoint blockade. This antibody is designed for use in research focused on cancer immunotherapy and the modulation of immune responses.

Zolbetuximab (IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2, a tight junction protein predominantly expressed in certain epithelial cells. This antibody facilitates the selective eradication of Claudin-18.2-positive cells by engaging immune effector mechanisms. It is primarily utilized in scientific studies focused on gastrointestinal adenocarcinomas and pancreatic tumors, offering a critical tool for understanding and potentially targeting these malignancies.

The Anti-GPC-2 Antibody (CT3) is a chimeric mouse monoclonal antibody of the IgG1 kappa subtype, specifically designed to target human Glypican-2 (GPC-2). For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control. This antibody serves as a vital tool for the detection and study of GPC-2 expression in various research applications.

Abiprubart is a human IgG4 κ monoclonal antibody targeting CD40. For accurate experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Letolizumab (BMS-986004) is a monoclonal antibody engineered to specifically target CD40L. This antibody variant is designed as a mutant IgG1 isotype that lacks effector functions, notably Fc receptor binding and complement fixation capabilities. The primary therapeutic action of Letolizumab is to mitigate rejection and thromboembolism, effectively extending survival time in clinical settings. This makes it particularly valuable in research focused on immune response modulation and transplantation immunology.

Drozitumab (PRO 95780) is a human agonistic monoclonal antibody designed to specifically target and bind to the death receptor DR5. This interaction promotes apoptosis in tumor cells, thereby exhibiting potent antitumor activity. Drozitumab has demonstrated significant efficacy against rhabdomyosarcoma in research settings, making it a valuable tool for studies focused on this type of cancer.

The Anti-CLDN6 Antibody (DS-9606A) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells that specifically targets Claudin 6 (CLDN6). This antibody is composed of an IgG1 type heavy chain and a human kappa (huκ) type light chain, with a predicted molecular weight of 145.84 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is ideal for research applications focusing on the role of CLDN6 in cellular tight junctions and its implications in various disease states.

Cosfroviximab (c13C6-FR1) is a chimeric monoclonal antibody derived from both mouse and human sources, designed to target the glycoprotein of the Ebola virus (EBOV-GP). This antibody is specifically engineered for high specificity and affinity towards EBOV-GP, making it an essential tool for research into the pathogenesis and potential treatments of Ebola virus infections.

Ofatumumab is a fully human monoclonal antibody targeting the CD20 antigen on B lymphocytes. It functions primarily through the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), effectively lysing CD20-positive B cells. This antibody demonstrates potent efficacy in eliminating CD20-positive tumor cells, including those resistant to other drugs with low CD20 expression levels. Ofatumumab is particularly valuable in the study of chronic lymphocytic leukemia (CLL), offering insights into therapeutic resistance and disease progression mechanisms.

Zovostotug is a monoclonal antibody that specifically targets human CD163, a member of the scavenger receptor cysteine-rich (SRCR) superfamily, type 1 M130. This antibody is designed for precision in binding to CD163, which is predominantly expressed on the surface of macrophages and is involved in the clearance and endocytosis of hemoglobin/haptoglobin complexes. Zovostotug is an essential tool for researchers studying macrophage activation, inflammation processes, and the resolution of tissue damage, making it ideal for applications in immunology and cellular biology.

Encelimab is a monoclonal antibody targeting LAG-3 (Lymphocyte-activation gene 3). By inhibiting the interaction between LAG-3 and MHC class II molecules, Encelimab promotes T-cell activation and enhances immune responses. Studies have demonstrated that Encelimab, both as a monotherapy and in conjunction with an anti-PD-1 antibody, effectively reduces tumor volume in a lymphoma mouse model using A20 cell xenografts. This antibody is pivotal for research focused on immunotherapy and cancer immunology, particularly in understanding and manipulating T-cell responses in oncological models.

The Anti-CLEC14A Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CLEC14A, a marker implicated in angiogenesis and tumor biology. This antibody comprises an IgG1 heavy chain and a human kappa (huκ) light chain, exhibiting a predicted molecular weight of approximately 150 kDa. For isotype control in experimental procedures, the Human IgG1 kappa, Isotype Control is recommended. This product is essential for research focused on cancer, vascular biology, and related therapeutic development.

Samalizumab (ALXN 6000) is a humanized monoclonal antibody engineered to selectively target and bind to CD200, effectively inhibiting its interaction with the CD200 receptor (CD200R). This antibody is utilized in the study of multiple myeloma and B-cell chronic lymphocytic leukemia, offering a valuable tool for researchers exploring the pathophysiological roles and therapeutic potential of CD200-CD200R signaling in these hematological malignancies.

Bentracimab (PB 2452) is a high-affinity neutralizing monoclonal antibody designed to specifically bind to Ticagrelor and its major active circulating metabolite. This antibody is capable of rapidly reversing the antiplatelet effects of Ticagrelor, making it an essential tool for research into the pharmacodynamics and therapeutic management of Ticagrelor-induced platelet inhibition. Bentracimab offers significant potential for studies focused on cardiovascular therapeutics and anticoagulant reversal strategies.

Afasevikumab, also known as RG 7624, RO 5553110, and NI-1401, is a fully human monoclonal IgG1κ antibody designed to neutralize interleukin-17A (IL-17A) and interleukin-17F (IL-17F). This antibody exhibits potent anti-inflammatory properties by targeting and inhibiting the activity of these cytokines, which are crucial mediators in the pathogenesis of various inflammatory and autoimmune disorders. Afasevikumab is primarily utilized in research focused on the therapeutic potential in treating conditions characterized by excessive or aberrant IL-17 activity.

Revdofilimab (ABBV-368) is a human IgG1 monoclonal antibody designed as an agonist targeting OX40, a constituent of the TNF receptor superfamily. OX40 is predominantly expressed on subsets of activated and memory T cells as well as T regulatory cells. This antibody facilitates the modulation of immune responses, making it a valuable tool in immunological research and therapeutic development.

Plamotamab (XmAb-13676) is a human bispecific antibody designed to target CD3 and CD20 simultaneously. This antibody facilitates the recruitment of cytotoxic T cells to CD20-expressing tumor cells, promoting targeted cell-mediated cytotoxicity. In vivo studies have demonstrated that Plamotamab effectively induces tumor regression. Additionally, it is associated with a mild hematologic reaction, highlighting its potential therapeutic benefits with manageable side effects. This product is pivotal for research focused on innovative cancer immunotherapies, particularly in the context of hematologic malignancies.

The Anti-CD32/FcγRIIA Antibody (IV.3) is a chimeric monoclonal antibody of the mouse IgG2b class, specifically designed to target human CD32/FcγRIIA. This antibody serves as a critical tool for the study of immune response modulation via Fc receptors. For accurate experimental control, it is recommended to use Mouse IgG2b kappa as the isotype control. This antibody is ideal for applications in immunology research, particularly in the investigation of Fc receptor function and its role in disease pathogenesis.

Ulenistamab (PBP1510) is a pioneering humanized IgG1 monoclonal antibody designed to specifically target the pancreatic adenocarcinoma upregulated factor (PAUF). This antibody serves as a vital tool in the investigation of pancreatic cancer (PC), offering potential insights into disease mechanisms and therapeutic avenues.

KWAR23 is a monoclonal antibody targeting human Signal Regulatory Protein Alpha (SIRPα). This antibody exhibits high affinity for SIRPα, effectively inhibiting its interaction with CD47. KWAR23 has demonstrated potential in enhancing antitumor responses, particularly when used alongside tumor-opsonizing antibodies. It is primarily utilized in the study of cancer immunotherapy, offering a promising tool for investigating checkpoint blockade strategies and tumor immune evasion mechanisms.

Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody that specifically targets complement component C2. By binding to the Sushi-2 domain of C2, Empasiprubar effectively prevents the formation of C3 convertase, thereby inhibiting the activation of both the classical and lectin complement pathways upstream of C3. This inhibition is critical in mitigating the effects of complement-mediated autoimmune disorders, such as autoimmune hemolytic anemia, and in preventing antibody-mediated rejection in organ transplantation. Additionally, Empasiprubar has demonstrated potential in preventing neuroglial and lymphoconjunctival injuries in GM1 antibody-mediated mouse models, suggesting further applications in neuroinflammatory conditions. This antibody offers a promising therapeutic approach by targeting a key point in the complement activation cascade, providing broad utility in research focused on immune regulation and complement system-mediated diseases.

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

RGX-019 is a humanized monoclonal antibody currently under investigation as a drug candidate. It specifically targets the MER proto-oncogene tyrosine kinase (MERTK), a receptor tyrosine kinase implicated in the regulation of various cellular processes including survival, migration, and differentiation. This targeted approach holds potential for therapeutic applications in oncology and diseases characterized by abnormal cell proliferation and survival.

Hersintuzumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting ERBB2/HER2/CD340. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. Hersintuzumab is applicable in research focused on cancer biology, particularly in studies investigating the role of the ERBB2/HER2/CD340 in tumor growth and progression.

Forimtamig (RG-6324) is a bispecific antibody designed for T-cell engagement, targeting GPRC5D and CD3. This molecule adopts a 2+1 configuration, incorporating two high-affinity binding sites for GPRC5D and a single site for CD3. It is engineered with a P329G LALA mutation in the Fc domain, which reduces binding to Fcγ receptors and C1q without affecting its interaction with the neonatal Fc receptor. The recommended isotype control for Forimtamig is Human IgG1 kappa. This antibody is pivotal in research focused on modulating immune responses, particularly in the context of cancer immunotherapy.

Sevirumab (MSL-109) is a human IgG1 monoclonal antibody designed to neutralize cytomegalovirus (CMV). This antibody specifically targets CMV glycoprotein H (gH) complexes, effectively inhibiting viral replication. It demonstrates potent antiviral activity with an EC50 value of 0.3 μg/mL, making it a valuable tool for research into CMV pathogenesis and therapeutic intervention.

The Anti-TSLP Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets thymic stromal lymphopoietin (TSLP), an important cytokine involved in the initiation of allergic inflammation and immune response. This antibody is composed of the human IgG1 heavy chain and the human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the role of TSLP in immune regulation and allergic diseases.

Pritoxaximab is a monoclonal antibody of the IgG1κ isotype designed to specifically target and neutralize Shiga toxin type 1. This antibody serves as a crucial tool in the study of bacterial pathogenesis and can be applied in research focused on the therapeutic intervention of diseases caused by Shiga toxin-producing bacteria.

Sonepcizumab (LT 1009) is a fully human monoclonal antibody targeting sphingosine-1-phosphate (S1P). This antibody is designed for investigational use in studies focusing on metastatic renal cell carcinoma (mRCC), offering a potential tool for understanding the role of S1P in tumor progression and metastasis.

Vofatamab (B-701) is a monoclonal antibody that selectively targets the fibroblast growth factor receptor 3 (FGFR3). It effectively inhibits the activation of both the wild-type and mutant forms of this receptor. This antibody is particularly useful in research focused on metastatic urothelial carcinoma (mUC), providing a critical tool for investigating the role of FGFR3 in cancer progression and potential therapeutic interventions.

Briakinumab (ABT-874) is a fully human monoclonal antibody that specifically targets and neutralizes the p40 subunit shared by the cytokines IL-12 and IL-23. This antibody's action inhibits the signaling pathways of both interleukin-12 (IL-12) and interleukin-23 (IL-23), which are crucial mediators in the inflammatory processes associated with autoimmune disorders. Briakinumab is utilized extensively in research focused on autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, providing valuable insights into the pathophysiology of these conditions and potential therapeutic approaches.